Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) have earned a consensus recommendation of “Moderate Buy” from the six research firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $17.00.

Several research firms have weighed in on VRCA. TD Cowen restated a “buy” rating on shares of Verrica Pharmaceuticals in a report on Wednesday, January 7th. Loop Capital set a $17.00 target price on Verrica Pharmaceuticals in a research report on Thursday, December 18th. Zacks Research raised shares of Verrica Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Friday, January 9th. Brookline Capital Acquisition raised shares of Verrica Pharmaceuticals from a “hold” rating to a “buy” rating and set a $17.00 price target on the stock in a research note on Thursday, December 18th. Finally, Wall Street Zen lowered shares of Verrica Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. State Street Corp raised its position in Verrica Pharmaceuticals by 14.1% during the fourth quarter. State Street Corp now owns 23,481 shares of the company’s stock valued at $195,000 after purchasing an additional 2,900 shares during the period. Man Group plc purchased a new stake in Verrica Pharmaceuticals during the 4th quarter valued at $94,000. Quadrature Capital Ltd purchased a new stake in Verrica Pharmaceuticals during the 4th quarter valued at $99,000. Beck Mack & Oliver LLC bought a new stake in Verrica Pharmaceuticals in the fourth quarter worth $100,000. Finally, Bridgeway Capital Management LLC purchased a new position in Verrica Pharmaceuticals during the third quarter worth $52,000. Hedge funds and other institutional investors own 42.45% of the company’s stock.

Verrica Pharmaceuticals Stock Down 1.8%

Shares of Verrica Pharmaceuticals stock opened at $5.37 on Thursday. Verrica Pharmaceuticals has a twelve month low of $3.28 and a twelve month high of $9.82. The business has a 50-day moving average price of $7.13 and a 200-day moving average price of $5.88. The firm has a market cap of $85.87 million, a price-to-earnings ratio of -1.57 and a beta of 1.47.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.